论文部分内容阅读
目的研究分析SP方案与XELOX方案治疗晚期胃癌的疗效与安全性。方法给予本院收治的84例晚期胃癌患者,分别采用SP方案与XELOX方案治疗,对比分析治疗效果。结果治疗后,两组治疗有效率对比差异无统计学意义(P>0.05),但两组不良反应发生率对比差异有统计学意义(P<0.05)。结论在对晚期胃癌患者实施治疗时,SP方案与XELOX方案效果相同,因此在对患者实施治疗时,应根据患者具体临床资料选择合适的治疗方案。
Objective To study the efficacy and safety of SP regimen and XELOX regimen in the treatment of advanced gastric cancer. Methods Eighty-four patients with advanced gastric cancer admitted to our hospital were treated with SP regimen and XELOX regimen respectively, and the therapeutic effects were compared. Results After treatment, there was no significant difference between the two groups in the treatment efficiency (P> 0.05), but there was significant difference in the incidence of adverse reactions between the two groups (P <0.05). Conclusion In the treatment of patients with advanced gastric cancer, the efficacy of SP regimen is the same as that of XELOX regimen. Therefore, the appropriate treatment regimen should be selected according to the specific clinical data of the patients during the treatment.